Considering Available Drugs for Fragile X: My Favorite Combination (So Far)

Which of the available drugs are best for managing fragile X syndrome? Most drugs have “off-target” effects which can have key advantages in some cases.

Read More »

fNIRS to Measure Treatment Response in Young Children with Fragile X

FRAXA Research Foundation has awarded a $90,000 research grant to Dr. Craig Erickson and Dr. Elizabeth Smith at Cincinnati Children’s Hospital to test functional near-infrared spectroscopy (fNIRS), in children who have Fragile X syndrome. fNIRS is safe, non-invasive, and easily-tolerated. It uses light sources and sensors on the scalp to build a heat map of the brain in action.

Read More »

Less Active Immune System Evident in Fragile X Patients, Study Suggests

People with Fragile X syndrome are more likely to develop infections, but are less susceptible to autoimmune disorders than the overall population, a new study found. Taken together, this suggests that the immune system is underactive in this patient population. The study, titled, “The phenotypical implications of immune dysregulation in Fragile X syndrome,” was published in the European Journal of Neurology.

Read More »
Dr. Jonny Lovelace and Dr. Khaleel Razak

Results Reported: Using EEG Responses to Sound for Fragile X Drug Discovery

Jonathan Lovelace, a FRAXA funded Postdoc at UC Riverside, has made some exciting EEG findings over the past few years studying auditory hypersensitivity in mice and therapeutic drug treatments. A big obstacle in FXS research has been establishing reliable, unbiased, and translation relevant biomarkers that can be used to determine the effectiveness of therapies. One of the most important discoveries they have made is the striking similarity in EEG biomarkers between mice and humans.

Read More »
Dan Vershbow, Mary Higgins Clark, Michael Tranfaglia, Katie Clapp

A Tribute to Mary Higgins Clark

Mary Higgins Clark, beloved author and Fragile X advocate, passed at 92. Her $1M gift in 1997 helped put FRAXA on the map for research.

Read More »

Should You Participate in a Fragile X Clinical Trial?

A Fragile X clinical trial of a new PDE4D allosteric inhibitor from Tetra Therapeutics is nearly complete. Right now there are 3 remaining spots open to males 18-45 years of age with Fragile X syndrome. Dr. Elizabeth Berry-Kravis at the Rush University Medical Center in Chicago is leading this trial. The drug being studied has a unique mechanism of action that might improve cognitive and memory function.  

Read More »

Meet Will!

Meet #FriendofFRAXA Will! If you would like to nominate someone as a #FriendofFRAXA, we welcome all who have been touched by Fragile X, including friends, grandparents, siblings, professionals and companions alike to become a #FriendofFRAXA with the goal of putting a face to Fragile X for those who may not know someone directly.

Read More »

Thankful is an Understatement

Thanks to our incredible supporters, FRAXA met its $750K goal before 2020—proof that together, we can overcome any challenge!

Read More »

31 Nights of Light with FRAXA Research Foundation

The Boston Prudential Center featured FRAXA in its 31 Nights of Light, shining bright for Fragile X awareness this December!

Read More »

Boston Bruins Fans and Volunteers raise $18,500 for Fragile X Research

The Bruins Foundation selected FRAXA again for their 50/50 raffle, raising $37K during the Nov 23 game against the Minnesota Wild!

Read More »

Meet Caleb!

Meet #FriendofFRAXA Caleb! If you would like to nominate someone as a #FriendofFRAXA, we welcome all who have been touched by Fragile X, including friends, grandparents, siblings, professionals and companions alike to become a #FriendofFRAXA with the goal of putting a face to Fragile X for those who may not know someone directly.

Read More »

Jim Cantore Assists on an Absolutely Successful #GivingTuesday

With Jim Cantore’s help and 130+ donors, FRAXA raised $95,500 on #GivingTuesday—funding two year-long Fragile X research grants!

Read More »

New Partners Aim to Accelerate the Discovery and Repurposing of Medicines for Rare Neurological Diseases

First Healx secured $56M in new financing to launch a global Rare Treatment Accelerator program to tackle Fragile X syndrome and 39 other rare diseases. Now they have built a partnership with Boehringer Ingelheim worth millions. It all started with a small FRAXA grant to Healx to repurpose available drugs for Fragile X.

Read More »

Meet Jed & Kit!

Meet #FriendofFRAXA Jed & Kit! If you would like to nominate someone as a #FriendofFRAXA, we welcome all who have been touched by Fragile X, including friends, grandparents, siblings, professionals and companions alike to become a #FriendofFRAXA with the goal of putting a face to Fragile X for those who may not know someone directly.

Read More »

Genes & Gems Raises $56,000 for Fragile X Research!

Ohio families hosted the unforgettable Genes & Gems event on Nov 16, 2019 at the Renaissance Columbus Hotel to support FRAXA research.

Read More »

Meet Jack!

Meet #FriendofFRAXA Jack! If you would like to nominate someone as a #FriendofFRAXA, we welcome all who have been touched by Fragile X, including friends, grandparents, siblings, professionals and companions alike to become a #FriendofFRAXA with the goal of putting a face to Fragile X for those who may not know someone directly.

Read More »
Elle Skala, Tracy King, Christie Rogers, Mary Beth Busby

National Institutes of Health Releases Fragile X Strategic Plan

FRAXA Program Coordinator, Elle Skala, and long time FRAXA supporter and previous Board Member, Mary Beth Busby, traveled to the National Institutes of Health earlier this week. The timing of this meeting was perfect because the National Institutes of Health (NIH) just released their long-anticipated Strategic Plan for Fragile X Syndrome, FXTAS, and FXPOI. It will guide federal Fragile X research funding for at least the next five years and open the door for continued funding of the Fragile X Research Centers of Excellence.

Read More »

Meet Anthony!

Meet #FriendofFRAXA Anthony! If you would like to nominate someone as a #FriendofFRAXA, we welcome all who have been touched by Fragile X, including friends, grandparents, siblings, professionals and companions alike to become a #FriendofFRAXA with the goal of putting a face to Fragile X for those who may not know someone directly.

Read More »

Meet Jagger!

Meet #FriendofFRAXA Jagger! If you would like to nominate someone as a #FriendofFRAXA, we welcome all who have been touched by Fragile X, including friends, grandparents, siblings, professionals and companions alike to become a #FriendofFRAXA with the goal of putting a face to Fragile X for those who may not know someone directly.

Read More »

A Personal Touch to Supporting Fragile X Research

As the holidays near, take a moment to make a difference. Your year-end gift to FRAXA helps change the future for Fragile X families.

Read More »
Dr. Bettio, Dr. Christie, Dr. Thacker

Targeting Adiponectin to Treat Fragile X Syndrome

FRAXA Research Foundation has awarded a $30,000 research grant to principal investigator Brian Christie, PhD, and postdoctoral fellows Jonathan Thacker, PhD, and Luis Bettio, PhD, at the University of Victoria. They are investigating whether boosting the hormone adiponectin can effectively treat Fragile X syndrome. This project is funded in partnership with the Fragile X Research Foundation of Canada, which is providing an additional $15,000.

Read More »
Matty & Jackson FriendofFRAXA

Meet Matty & Jackson!

Meet #FriendofFRAXA Matty & Jackson! If you would like to nominate someone as a #FriendofFRAXA, we welcome all who have been touched by Fragile X, including friends, grandparents, siblings, professionals and companions alike to become a #FriendofFRAXA with the goal of putting a face to Fragile X for those who may not know someone directly.

Read More »

Healx Raises $56M to use AI to Find Treatments for Fragile X & Other Rare Diseases

Healx has secured $56M in new financing to build a clinical-stage portfolio for rare diseases, including treatments for Fragile X syndrome, and to launch a global Rare Treatment Accelerator program. Where the traditional drug discovery model takes more than a decade and can run into the billions of dollars, Healx’s AI-driven approach makes the process faster, more efficient and cost-effective.

Read More »

FRAXA Biotech Games, It Can Only Happen in an Open Community

The FRAXA Biotech Games lit up Cambridge Crossing with biotech teams uniting to raise funds and awareness for Fragile X research.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (37)